Samso News: Actinogen Medical Limited — $4.3m Non-Dilutive Funding Secured to Extend Alzheimer’s Trial Runway.
- Noel Ong
- 1 day ago
- 4 min read
Announcement
Actinogen secures $4.3m of non-dilutive R&D tax funding - 27 January 2026 (view the announcement)
Here is a story that Samso continues to follow, Actinogen Medical Limited as they continue to focus on late-stage clinical execution in Alzheimer’s disease and its disciplined approach to funding. This Samso News update is relevant as it strengthens the Company’s balance sheet without shareholder dilution while supporting the final stages of a pivotal clinical program. The ability to extend cash runway while maintaining trial momentum is a key consideration for investors monitoring clinical-stage biotechnology companies.
Introducing Actinogen Medical Limited– Advancing Xanamem Through Late-Stage Alzheimer’s Development
Actinogen Medical Limited (ASX: ACW) is progressing its lead drug candidate, Xanamem (emestedastat), through the XanaMIA Phase 2b/3 Alzheimer’s disease clinical trial being conducted across Australia and the United States. The Company is developing Xanamem as a once-daily oral therapy targeting cortisol regulation in the brain, to slow disease progression in patients with mild to moderate Alzheimer’s disease.
Highlights – Non-Dilutive Funding Strengthens Clinical Delivery Pathway
Actinogen secured $4.3 million as a second tranche of non-dilutive funding from Endpoints Capital, backed by the Company’s forecast FY26 Research and Development Tax Incentive (RDTI) rebate.
The funding forms part of a previously announced overall facility of up to $13.8 million, originally disclosed on 30 June 2025.
Proceeds will support the XanaMIA Phase 2b/3 Alzheimer’s disease trial, which is now fully enrolled with 220 patients across 35 sites in Australia and the United States.
Funding will also support the commencement of the open-label extension (OLE) of the XanaMIA trial, expected to begin during the current quarter.
Additional funds will be allocated to general working capital, extending Actinogen’s cash runway to mid-2026.
Leadership Commentary
Actinogen Chief Financial Officer, Mr Will Souter, commented:
“The funding secured today as part of our agreement with Endpoints Capital further strengthens our balance sheet as we rapidly approach the interim analysis for our Alzheimer’s phase 2b/3 clinical trial and progress the trial through to final topline results in November, and reaffirms our cash runway out to mid-2026.”
Near-term Milestones to Watch
Interim analysis of the XanaMIA Phase 2b/3 Alzheimer’s disease trial, expected in late January 2026.
Commencement of the XanaMIA open-label extension (OLE) in Q1 2026.
Final topline results from the XanaMIA trial, expected in November 2026.
Samso Concluding Comments
This up is all about Actinogen getting cash in the bank for work rather than new clinical results. Funding is always important for businesses and this is no different for Actinogen as it creates visibility at an important stage of development.
The XanaMIA program remains the Company’s core value driver and with enrolment complete, the next phase is data-driven rather than operational.
The commencement of the open-label extension provides a longer-term safety and exposure pathway for patients. This may also support future regulatory discussions.
For investors, this update reinforces the importance of upcoming trial readouts. As always, progress will ultimately be assessed through clinical outcomes rather than funding announcements alone.
Market Implication - The Investor Lens
The market journey for Actinogen has been very interesting over the last 12 months. Looking at Figure 1, you can see the up and down of investors interest in the stock. The last six months is what I am more interested in as this looks like a nice momentum being created.
Figure 1: The share price chart for Actinogen as of the 10th February 2026. (source: commsec)
Samso has been writing on this journey and apart from the last month where there has been a devaluation of the share price, I think the potential of what Actinogen could bring with more positive results out weight the potential negatives. In saying that, we will have to always consider that a good old DYOR is required as there are no such thing as a sure thing when it comes to investments.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments